H
Hao Zhou
Publications - 9
Citations - 399
Hao Zhou is an academic researcher. The author has contributed to research in topics: Titer & Monoclonal antibody. The author has an hindex of 7, co-authored 9 publications receiving 167 citations.
Papers
More filters
Posted ContentDOI
Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants
Takuya Tada,Hao Zhou,Marie I. Samanovic,Belinda M Dcosta,Amber Cornelius,Mark J. Mulligan,Nathaniel R. Landau +6 more
TL;DR: In this paper, neutralizing antibody titers elicited by mRNA-based and an adenoviral vector-based vaccine against variant pseudotyped viruses were compared, showing that BNT162b2 and mRNA-1273-elicited antibodies showed modest neutralization resistance against Beta, Delta, Delta plus and Lambda variants.
Posted ContentDOI
Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies
TL;DR: In this paper, the authors tested monoclonal antibodies REGN10933 and REGN10987 that are used in combination, for their ability to neutralize SARS-CoV-2 variants B.1.7, mink cluster 5 and COH.
Journal ArticleDOI
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
Takuya Tada,Belinda M Dcosta,Marie I. Samanovic,Ramin S. Herati,Amber Cornelius,Hao Zhou,Ada Vaill,Wes Kazmierski,Mark J. Mulligan,Nathaniel R. Landau +9 more
TL;DR: In this article, the authors show that convalescent-phase sera neutralize pseudotyped viruses with the B.1.7, B.351 and B. 1.248 with only a 3fold decrease in titer, an effect attributable to E484K.
Posted ContentDOI
The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies
Takuya Tada,Hao Zhou,Belinda M Dcosta,Marie I. Samanovic,Mark J. Mulligan,Nathaniel R. Landau +5 more
TL;DR: In this article, the authors showed that B.1.617 and B.618 have mutations within the spike protein that may contribute to their increased transmissibility and that could potentially result in re-infection or resistance to vaccine-elicited antibody.
Journal ArticleDOI
Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera.
Takuya Tada,Hao Zhou,Belinda M Dcosta,Marie I. Samanovic,Mark J. Mulligan,Nathaniel R. Landau +5 more
TL;DR: In this article, the authors used lentivirus pseudotyped by variant spikes to measure their neutralization by convalescent sera, vaccine-elicited and Regeneron therapeutic antibodies, and ACE2 affinity.